Search This Blog

Wednesday, November 7, 2018

Sanofi: NEJM publishes positive results from Praluent cardio trial


New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
  • Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
  • Praluent was associated with a 15% lower risk of death from any cause (hazard ratio [HR] 0.85; 95% confidence interval [CI], 0.73 to 0.98)1
  • Additional analyses, including mortality, to be presented at upcoming American Heart Association Scientific Sessions, November 10-12
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)